Literature DB >> 18381579

Inhibition of CYP21A2 enzyme activity caused by novel missense mutations identified in Brazilian and Scandinavian patients.

F C Soardi1, M Barbaro, I F Lau, S H V Lemos-Marini, M T M Baptista, G Guerra-Junior, A Wedell, S Lajic, M P de Mello.   

Abstract

BACKGROUND: Most patients with 21-hydroxylase deficiency carry CYP21A1P-derived mutations, but an increasing number of novel and rare mutations have been reported in disease-causing alleles.
OBJECTIVE: Functional effects of three novel (p.G56R, p.L107R, p.L142P) and one recurrent (p.R408C) CYP21A2 mutations were investigated. The degree of enzyme impairment caused by p.H62L alone or combined to p.P453S was also analyzed.
DESIGN: The study included 10 Brazilian and two Scandinavian patients. To determine the deleterious role of each mutant protein, in vitro assays were performed in transiently transfected COS-1 cells. For a correct genotype-phenotype correlation, the enzymatic activities were evaluated toward the two natural substrates, 17-hydroxyprogesterone and progesterone.
RESULTS: Low levels of residual activities obtained for p.G56R, p.L107R, p.L142P, and p.R408C mutants classified them as classical congenital adrenal hyperplasia mutations, whereas the p.H62L showed an activity within the range of nonclassical mutations. Apparent kinetic constants for p.H62L confirmed the nonclassical classification as the substrate binding capacity was within the same magnitude for mutant and normal enzymes. A synergistic effect was observed for the allele bearing the p.H62L+p.P453S combination because it caused a significant reduction in the enzymatic activity.
CONCLUSIONS: We describe the functional analysis of five rare missense mutations identified in Brazilian and Scandinavian patients. The p.G56R, p.L107R, and p.L142P are reported for the first time. Most probably these novel mutations are closer to null than the p.I172N, but for the p.G56R, that might not be the case, and the p.H62L is definitely a nonclassical mutation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381579     DOI: 10.1210/jc.2007-2594

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Gabriela P Finkielstain; Wuyan Chen; Sneha P Mehta; Frank K Fujimura; Reem M Hanna; Carol Van Ryzin; Nazli B McDonnell; Deborah P Merke
Journal:  J Clin Endocrinol Metab       Date:  2010-10-06       Impact factor: 5.958

2.  Human Cytochrome P450 21A2, the Major Steroid 21-Hydroxylase: STRUCTURE OF THE ENZYME·PROGESTERONE SUBSTRATE COMPLEX AND RATE-LIMITING C-H BOND CLEAVAGE.

Authors:  Pradeep S Pallan; Chunxue Wang; Li Lei; Francis K Yoshimoto; Richard J Auchus; Michael R Waterman; F Peter Guengerich; Martin Egli
Journal:  J Biol Chem       Date:  2015-04-08       Impact factor: 5.157

3.  Functional analysis of human cytochrome P450 21A2 variants involved in congenital adrenal hyperplasia.

Authors:  Chunxue Wang; Pradeep S Pallan; Wei Zhang; Li Lei; Francis K Yoshimoto; Michael R Waterman; Martin Egli; F Peter Guengerich
Journal:  J Biol Chem       Date:  2017-05-24       Impact factor: 5.157

4.  Development of CYP21A2 Genotyping Assay for the Diagnosis of Congenital Adrenal Hyperplasia.

Authors:  Mayara Jorgens Prado; Simone Martins de Castro; Cristiane Kopacek; Maricilda Palandi de Mello; Thaiane Rispoli; Tarciana Grandi; Cláudia Maria Dornelles da Silva; Maria Lucia Rosa Rossetti
Journal:  Mol Diagn Ther       Date:  2017-12       Impact factor: 4.074

5.  Normal bone health in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy.

Authors:  Juliano Henrique Borges; Daniel Minutti de Oliveira; Sofia Helena Valente de Lemos-Marini; Bruno Geloneze; Gil Guerra-Júnior; Ezequiel Moreira Gonçalves
Journal:  Osteoporos Int       Date:  2021-08-18       Impact factor: 4.507

6.  Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency.

Authors:  Maria I New; Moolamannil Abraham; Brian Gonzalez; Miroslav Dumic; Maryam Razzaghy-Azar; David Chitayat; Li Sun; Mone Zaidi; Robert C Wilson; Tony Yuen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

7.  Structure-based analysis of five novel disease-causing mutations in 21-hydroxylase-deficient patients.

Authors:  Carolina Minutolo; Alejandro D Nadra; Cecilia Fernández; Melisa Taboas; Noemí Buzzalino; Bárbara Casali; Susana Belli; Eduardo H Charreau; Liliana Alba; Liliana Dain
Journal:  PLoS One       Date:  2011-01-11       Impact factor: 3.240

8.  Novel deletion alleles carrying CYP21A1P/A2 chimeric genes in Brazilian patients with 21-hydroxylase deficiency.

Authors:  Fernanda B Coeli; Fernanda C Soardi; Renan D Bernardi; Marcela de Araújo; Luciana C Paulino; Ivy F Lau; Reginaldo J Petroli; Sofia H V de Lemos-Marini; Maria T M Baptista; Gil Guerra-Júnior; Maricilda P de-Mello
Journal:  BMC Med Genet       Date:  2010-06-29       Impact factor: 2.103

9.  H62L Mutation of CYP21A2 Identified in the Non-classical Form of 21-Hydroxylase Deficiency.

Authors:  Keisuke Nagasaki; Takeshi Usui; Tadashi Asami; Yohei Ogawa; Toru Kikuchi; Makoto Uchiyama
Journal:  Clin Pediatr Endocrinol       Date:  2009-11-11

10.  A novel 9-bp insertion detected in steroid 21-hydroxylase gene (CYP21A2): prediction of its structural and functional implications by computational methods.

Authors:  Sudhisha Dubey; Susan Idicula-Thomas; Mohammad Anwaruddin; Chinnaraj Saravanan; R Raveendra Varma; Anurupa Maitra
Journal:  J Biomed Sci       Date:  2009-01-08       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.